Selank vs Semax: the calm one and the sharp one

Two peptides come out of the same Soviet-era lab, get sold on the same forums, and do almost opposite things. Selank takes the edge off. Semax sharpens it. One is a calm peptide, the other a focus peptide — and the forums stack them side by side and tell you to pick the better one, as if they were two brands of the same tool.

They’re not. The better question isn’t which one wins. It’s which problem you’re actually trying to solve. Get that right and the choice mostly makes itself.

Calm or sharp — which problem is yours

Selank is the calm one. The pitch: take anxiety down a notch and leave your head clear — the good part of a benzodiazepine without the sedation, the fog, or the habit forming underneath. If you want to be steadier under load without dulling the edge that makes you good at what you do, that’s the target it’s built for.

Semax is the sharp one. The pitch: a quicker, cleaner head — better focus, more mental stamina. It nudges up BDNF, the brain’s own grow-and-repair signal, the one behind learning and memory. That’s not a caffeine buzz. That’s closer to tuning the machinery.

So the split is clean before you read a single study. Anxious and foggy when the pressure’s on? That’s the Selank case. Flat, scattered, can’t hold a thought? That’s the Semax one. Wanting both at once is the honest reason people stack them — and also where the marketing quietly stops mentioning that the two were built for different jobs.

Two peptides, one Moscow lab

Both trace back to one institute and one bet. The Russian Academy group around Nikolai Miasoedov spent the late Soviet years on a single idea: your body already makes powerful neuroactive peptides, but it breaks them down in minutes. So take a fragment of one. Bolt on a small tail so it survives longer. See what it does.

Selank is that trick pointed at tuftsin — a tiny four-part peptide your immune system snips off an antibody, with mild calming activity of its own. Add a three-part Pro-Gly-Pro tail and you get a seven-residue peptide that lasts hours instead of minutes and heads for the brain.

Semax is the same trick pointed at ACTH, the stress hormone that tells your body to dump cortisol. Keep the four-residue piece that acts on the brain — Met-Glu-His-Phe — drop the part that raises cortisol, add the same Pro-Gly-Pro tail. Seven residues again. You get the alert signal without the stress riding shotgun.

Same lab, same tail, same logic — aimed at two different starting molecules. That’s why they read like siblings and behave like strangers.

What the human file actually holds

Here’s the part that surprises people. Both peptides have more human data behind them than most things sold in this corner of the internet. It’s just all in Russian.

Selank’s file is anxiety. Zozulia and colleagues (2008) put it head-to-head against medazepam — a benzodiazepine — in 62 adults with anxiety and neurasthenia, and reported comparable calming plus a mild lift in energy and focus, the opposite of the usual benzo drag. Medvedev and colleagues (2014) ran it against phenazepam in 60 patients and saw the same shape — no significant difference in anxiety relief between the two — with the calm lasting roughly a week after the last dose. Controlled trials, against real drugs, reported straight.

Semax’s file is the brain under injury. Gusev and colleagues (1997) gave it to 30 patients in the acute window of ischemic stroke, against 80 matched controls, and reported faster recovery of movement and cerebral function — the work that grounded semax’s Russian authorisation for stroke. Dolotov and colleagues (2006) pinned the mechanism in rat brain: semax binds and raises BDNF in the regions tied to memory and learning.

Now the boundary, said plainly. Every study above is single-cluster Russian work, published in Russian, inside an evaluation tradition Western regulators don’t treat as the last word. No independent lab outside that circle has reproduced it in English. And none of it looked at the people actually buying these two — healthy adults chasing calm or focus, not stroke patients or diagnosed anxiety cases. The 2026 Sports Medicine review by Mendias and Awan is blunt about the wider grey market both sit inside: unapproved compounds moving largely outside regulatory oversight, human safety data scarce. Selank and semax don’t even make its named list — which is the tell. The Russian peptide tradition sits outside the Western review literature entirely.

So it’s the same verdict for each. Real evidence. Real gap.

Where the FDA splits them apart

This is where the two stop looking like siblings at all.

Semax is on the FDA Pharmacy Compounding Advisory Committee’s July 24, 2026 docket, per Federal Register notice 2026-07361, reviewed alongside DSIP and Epitalon under the indications cerebral ischemia, migraine, and trigeminal neuralgia. Read those carefully — they’re neurological conditions, not the sharper-at-your-desk pitch the consumer market runs on. And a PCAC review isn’t approval. It’s an advisory committee weighing whether licensed pharmacies can compound a substance at all; what that vote can and can’t do is its own subject, covered in what a PCAC review actually is. The short version: US regulators are about to take their first formal, public look at semax — for its stroke-adjacent uses, not the nootropic one.

Selank gets none of that. It’s not on the July 2026 wave, not on the early-2027 one, and it’s never once faced a PCAC vote. It simply sits outside the process — a research chemical in the US, no FDA approval, no application on file. Buy selank in 2026 and you’re buying the same unregulated supply you were a year ago.

Anti-doping handles them alike, and stricter than the printed list looks. Neither is named outright on the WADA prohibited list. Both land inside the non-approved-substances category anyway, which is written broadly enough to catch a peptide like either of these. If you get tested, treat both as off-limits. A missing name isn’t a clearance.

So which one’s for you

Strip it back to the decision you came for. Selank if the problem is anxiety — a steadier head under load, without the benzodiazepine tax. Semax if the problem is focus — a quicker, sharper head, betting on BDNF. Pick the problem, not the peptide, and the answer stops being a coin-toss between two compounds and starts being obvious.

Then hold whichever answer you land on loosely. The Russian record is real for each — and for each it’s the opening of the case, not the close. The trial that would settle it — selank against placebo in healthy anxious adults, semax against placebo in healthy sharp ones — is the same trial nobody has paid to run. Calm or sharp, the honest status is identical. Promising. Unfinished.

Whichever one fits your problem, the version worth having isn’t a dropper bottle from a research-chemical checkout that can’t tell you what’s really inside it. It’s a physician who knows what each peptide has evidence for and what it doesn’t, a US-licensed pharmacy making it to spec, and a lab result on every batch before it ships. Making that the default is the entire point of Wolverine Health. It can’t open until the regulation moves — the honest reason it hasn’t yet — and July 24 is the next real marker on that road, the day semax goes in front of PCAC. Leave your email. The day the calm one or the sharp one becomes something a physician can actually put in your hand, we’ll come find you.